Research & Development Programme 3
Programme 3 is a cannabinoid derivative with an undisclosed indication and we plan to be ready for pre-clinical stage during 2023. Both programmes 3 and 4 have significantly advanced as a result of our worldwide exclusive licence from Canopy Growth Corporation which includes 335 cannabinoid derivatives, and 14 patent families. Programme 3 will be advanced in partnership with Dalriada and Oxford StemTech.